Sarcoma Program Director News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Sarcoma Program Director. Real-time updates on events, politics, business and more.

Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS) -December 04, 2023 at 07:02 am EST

December 4, 2023

TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 -- Polaris Group , today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with...

T Ai Pei Gina Lee Washington University In St Sarcoma Program Polaris Group Combo Strategy

Source: marketscreener.com

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

August 4, 2022

HOUSTON, Aug. 04, 2022 -- Salarius Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the... | August 4, 2022

New York United States Oregon Health Sciences University Memorial Sloan Kettering Cancer Center Fox Chase Cancer Center Washington University

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Sarcoma Program Director News Today

Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS) -December 04, 2023 at 07:02 am EST

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Explore More Categories